Role of targeted therapy in metastatic colorectal cancer

Table 4 Treatment outcome by anti-epidermal growth factor receptor therapy as first-line treatment in metastatic colorectal cancer with RAS wild type

Trial name	Regimens	n	ORR	PFS (mo)	OS (mo)
CRYSTAL	FOLFIRI + Cetuximab	178	66.3%	11.4	28.4
	FOLFIRI	189	38.6%	8.4	20.2
	(HR, P-value)		OR = 3.31	HR = 0.56	HR = 0.69
			P < 0.001	P = 0.0002	P = 0.0024
PRIME	FOLFOX + Panitumumab	259	-	10.1	25.8
	FOLFOX	253	-	7.9	20.2
	(HR, P-value)		-	HR = 0.72	HR = 0.77
				P = 0.004	P = 0.009
PEAK	FOLFOX + Panitumumab	88	63.6%	13.0	41.3
	FOLFOX + Bevacizumab	82	60.5%	9.5	28.9
	(HR, P-value)		-	HR = 0.65	HR = 0.63
				P = 0.029	P = 0.058
FIRE-3	FOLFIRI + Cetuximab	171	65%	10.4	33.1
	FOLFIRI + Bevacizumab	171	60%	10.2	25.6
	(HR, P-value)		OR = 1.28	HR = 0.93	HR = 0.70
			P = 0.32	P = 0.54	P = 0.011
CALGB/SWOG 80405	Chemotherapy1 + Cetuximab	270	68.6%	11.4	32.0
	Chemotherapy1 + Bevacizumab	256	53.8%	11.3	31.2
	(HR, P-value)		P < 0.01	HR = 1.1	HR = 0.9
				P = 0.31	P = 0.4

¹Chemotherapy regimens were FOLFOX or FOLFIRI. ORR: Objective response rate; PFS: Progression-free survival; OS: Overall survival; HR: Hazard ratio; OR: Odds ratio; FOLFIRI: Bolus and infusional 5-fluorouracil/leucovorin/irinotecan; FOLFOX: Bolus and infusional 5-fluorouracil/leucovorin/oxaliplatin.